Tarsus Pharmaceuticals (TARS) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Tarsus Pharmaceuticals (TARS) do?
Tarsus Pharmaceuticals Inc (TARS) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Produces and sells FDA-approved prescription eye drops that directly treat Demodex blepharitis by eliminating parasitic mites. Focuses on commercializing targeted treatments for eye diseases caused by Demodex mite infestations. It is worth $3.83B on the market and sold $682.63M over the last year.
- Market cap
- $3.83B
- P/E ratio
- None (reported a loss)
- Annual sales
- $682.63M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 18, 2026
Brands and businesses behind TARS
- Xdemvy: Prescription eye drops sold through pharmacies to treat eyelid inflammation caused by Demodex mites.
TARS’s flags, in plain English
Each flag is a number from Tarsus Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Wide Gross Margin
Gross margin of 93.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Stupid Cash
Can pay this year's bills 2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Insiders Hold
Insiders own 5.4% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Burning Cash
Losing money, profit margin of -102.9%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
1 more risk note open with the free trial. Try it free for 7 days.
Questions about TARS
How big is Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals’ market cap is $3.83B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $682.63M: what customers paid the company over the last year, before any costs.
What is TARS’s P/E ratio?
TARS has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with TARS?
The business relies almost entirely on commercial sales of a single approved prescription product, Xdemvy. That is one risk on Tarsus Pharmaceuticals’ card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Tarsus Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TARS’s filings on SEC.gov. The Margin Monkey is research, not advice.
